The Position of Milnacipran in Clinical Practice
Authors:
E. Češková
Authors‘ workplace:
Psychiatrická klinika LF MU a FN, Brno
přednostka prof. MUDr. E. Češková, CSc.
Published in:
Čes. a slov. Psychiat., 104, 2008, No. 8, pp. 420-425.
Category:
Comprehensive Reports
Overview
Dual –acting antidepressants are relatively recent class of antidepressants. They are represented mainly by serotonin and norepinephrine reuptake inhibitors (SNRI), e.g. venlafaxine, milnacipran and duloxetine. The article deals with milnacipran. The new indication, fibromyalgia, is discussed in more details. Nowadays, the individualized treatment is emphasized. Certain differences in the pharamacodynamics and pharmacokinetics of SNRI may be important to tailor the treatment choice to the patient. Some case reports of patients successfully treated with milnacipran are described.
Key words:
milnacipran, antidepressants, fibromyalgia, pharmacokinetics, pharmacodynamics.
Sources
1. Anders, M., Doležal, T.: Současné postavení milnacipranu mezi antidepresivy. Farmakoterapie, 2, 2006, s. 676-679.
2. Bisserbe, J. C.: Clinical utility of milnacipran in comparison with other antidepressants. Int. Clin. Psychopharmacol., 17, 2002, Suppl. 1, S43-S50.
3. Caspi, A., Sugden, K., Moffitt, T. E. et al.: Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science, 18, 2003, pp.291-293.
4. Češková E.: Duálně působící antidepresiva. Remedia, 16, 2006, s. 594-597.
5. Cohen, H., Buskila, D., Neumann, L., Ebstein, R. P.: Confirmation of an association between fibromyalgia and serotonin transporter promoter region (5-HTTLPR) polymorphism, and relationship to anxiety-related personality traits. Arthritis Rheum., 46, 2002, pp. 845-847.
6. Cunningham, J.: Milnacipran is a safe and effective treatment for fibromyalgia. CNS Spect., 13, 2008, pp. 465-466.
7. Fishbain, D.: Evidence-based data on pain relief with antidepressants. Ann. Med., 32, 2000, pp. 305-316.
8. Gendreau, R. M., Mease, P. J., Rao, S. R. et al.: Milnacipran: A potential new treatment of fibromyalgia. Arthritis Rheum., 48, 2003, Suppl. 9, S616.
9. Hrnčíř, Z.: Terapie fibromyalgie. In: Pavelka, K. et al.: Farmakoterapie revmatických onemocnění. Galén, 2005, Praha, s. 413-415.
10. Hrnčíř, Z., Dvořák, Z.: Fibromyalgie a chronický únavový syndrom. In: Pavelka, K, Rovenský, J. et al.: Klinická revmatologie. Galén, 2003, Praha, s. 679-683.
11. Kamata, M., Naito, S., Takahashi, H., Higuchi, H.: Milnacipran for the treatment of chronic pain. Hum. Psychopharmacol., 18, 2003, pp. 575-576.
12. Kolektiv autorů: Léčba deprese duálním antidepresivem Ixel. Sborník kazuistik, 2008, Janssen-Cilag.
13. Leo, R. J.: Chronic pain and comorbid depression. Curr. Treat. Options Neurol., 7, 2005, pp. 403-412.
14. Machado, M., Iskedjian, M., Ruin, I., Einarson, T. R.: Remission, dropouts, and adverse drug reaction rates in major depressive disordeer. A meta-analysis of head - to-head trials. Current Medicine Research and Opinions, 22, 2006, pp. 1825-1837.
15. Montgomery, S. A., Prost, J. F., Solles, A., Briket, M.: Efficacy and tolerability of milnacipran: An overview. Int. Clin. Psychopharmacol., 11, 1996, Suppl. 4, pp. 47-51.
16. Nagaoka, S., Ohno, M., Sekiguchi, A.: An open-label clinical trial of milnacipran in fibromyalgia syndrome with comorbid depressive symptoms. Int. J. Psychiatry Clin. Practice, 8, 2004, pp. 47-51.
17. Papakostas, G. I., Fava, M.: A meta-analysis of clinical trials comparing milnacipran, a serotonin-norpinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder. Eur. Neuropsychopharmacol., 17, 2007, pp. 32-36.
18. Poirier, M. F., Galinowski, A., Amado, I. et al.: Double-blind comparative study of the action of repeated administration of milnacipran versus placebo on cognitive functions in healthy volunteers. Hum. Psychopharmacol. Clin. Exp,. 19, 2004, pp. 1-7.
19. Puech, A., Montgomery, S. A., Prost, J. F. et al.: Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: An overview of its antidepressant activity and clinical tolerability. Int. Clin. Psychopharmacol., 12, 1997, pp. 99-108.
20. Puozzo, C., Albin, H., Vincon, G. et al.: Pharmacokinetics of milnacipran in liver impairment. Eur. J. Drug Metab. Pharmacokinet., 23, 1998, pp. 273-279.
21. Puozzo, C., Pozet, N., Deprez, D. et al.: Pharmacokinetics of milnacipran in renal impairment. Eur. J. Drug Metab. Pharmacokinet., 23, 1998, pp. 280-286.
22. Puozzo, C., Lens, S., Reh, C. et al.: Lack of interaction of milnacipran with the cytochrome P450 isoenzymes frequently involved in the metabolism of antidepressants. Clin. Pharmacokinet., 44, 2005, pp. 977-988.
23. Rochet, F., Marais, J., Serre, C., Pandini, E.: Effects of milnacipran on driving vigilance. Int. J. Psych. Clin. Practice, 8, 2004, pp. 109-115.
24. Rouet, R. H., Tisne-Versailles, J., Adamantidis, M. M. et al.: Comparative in vivo and in vitro study of the cardiac effects of milnacipran and imipramine. Fundam. Clin. Pharmacol., 3, 1989, pp. 237-244.
25. Sechter, D., Vandel, P., Weiller, E. et al.: A comparative study of milnacipran and paroxetine in outpatients with major depression. J. Affect. Disord., 83, 2005, pp. 233-236.
26. Shimamoto, E., Doi, N., Suwa, H. et al.: A case of postherpetic neuralgia improved by milnacipran. Jpn. J. Clin. Psychopharmacol., 5, 2002, pp. 197-200.
27. Stahl, S. M., Grady, M., Moret, Ch., Briket, M.: SNRIs: The pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr., 10, 2005, pp. 732-747.
28. Sugawara, Y., Higuchi, H., Yoshida K. et al.: Response rate obtained using milnacipran depending on the severity of depression in the treatment of major depressive patiens. Clin. Neuropharmacol., 29, 2006, pp. 6-9.
29. Švestka, J.: Nová psychofarmaka. Milnacipran-antidepresivum s prvním označením příslušnosti ke čtvrté generaci. Psychiatrie, 4, 2000, s. 46-56.
30. Tanikawa, H.: Efficacy of milnacipran in patients with chronic orthopedic pain including degenerative spondylosis and osteoarthritis. Int. J. Psychiatry Clin. Practice, 6, 2002, p. 255.
31. Toyofuku, A.: Efficacy of milnacipran for glossodynia patients. Int. J. Psychiatry Clin. Praktice, 7, 2003, Suppl. 1, pp. 23-24.
32. Toyofuku, A., Miyako, H.: A case of temporo-mandibular disorder with fibromyalgia treated with the antidepressant, milnacipran. Hum. Psychopharmacol., 19, 2004, pp. 357-358.
33. Utsunomiya, K., Ukita, T., Sirota, S.: A case of postherpetic neuralgia treated with milnacipran. Jpn. J. Clin. Psychopharmacol., 5, 2002, pp. 190-196.
34. Vandel, P., Sechter, D., Weiller, E. et al.: A comparative study of milnacipran and paroxetine in outpatients with major depression. Hum. Psychopharmacol., 19, 2004, pp. 585-586.
35. Vitton, O., Gendreau, M., Gendreau, J. et al.: A double-blind placebo controlled trial of milnacipran in the treatment of fibromyalgia. Hum. Psychopharmacol., 19, 2004, Suppl. 1, S27-S35.
36. Wolfe, F., Smythe, H. A., Yunus, M. B. et al.: The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee. Arthritis Rheum., 33, 1990, pp. 160-172.
37. Yoshida, K., Takahashi, H., Higuchi, H. et al.: Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Am. J. Psychiatry, 161, 2004, pp. 1575-1580.
38. Yoshimura, R., Mitoma, M., Sugita, A. et al.: Effects of paroxetine or milnacipran on serum brain-derived neurotrophic factor in depressed patients. Prog. Neuropsychopharmacol. Biol. Psychiatry, 31, 2007, pp. 1034-1037.
Labels
Addictology Paediatric psychiatry PsychiatryArticle was published in
Czech and Slovak Psychiatry
2008 Issue 8
Most read in this issue
- Application of Standardized Evaluating Scales in the Nursing Process in Psychiatry
- The Position of Milnacipran in Clinical Practice
- Borna Disease Virus (BDV) and Psychical Disorders
- Possibilities of Evaluation and Scaling Aggressiveness in Psychiatric Patients by Means of Personality Questionnaires